Lifeward Ltd(LFWD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LFWD Lifeward Ltd

Pre-Mkt 08-12 08:49:45 EDT

7.57

-0.14

-1.88%

High8.00	Low7.50	Vol3.62K
Open7.69	D1 Closing7.71	Amplitude6.48%
Mkt Cap21.29M	Tradable Cap11.19M	Total Shares2.81M
T/O27.83K	T/O Rate0.24%	Tradable Shares1.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LFWD","market":"US","secType":"STK","nameCN":"Lifeward Ltd","latestPrice":7.565,"timestamp":1786478400000,"preClose":7.71,"halted":0,"volume":3621,"delay":0,"changeRate":-0.018806744487678283,"floatShares":1478962,"shares":2814400,"eps":-19.239264,"marketStatus":"Pre-Mkt","change":-0.145,"latestTime":"08-12 08:49:45 EDT","open":7.69,"high":7.9999,"low":7.5,"amount":27825.0002094,"amplitude":0.064838,"askPrice":8.03,"askSize":3,"bidPrice":7.55,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-19.239264,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1786541400000},"marketStatusCode":1,"adr":0,"listingDate":1410494400000,"exchange":"NASDAQ","adjPreClose":7.565,"postHourTrading":{"tag":"盘后","latestPrice":7.565,"preClose":7.565,"latestTime":"19:46 EDT","volume":25,"amount":191.435,"timestamp":1786491965764,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7146798990221557,"impliedVol":1.4291,"impliedVolPercentile":0.8947},"requestUrl":"/m/hq/s/LFWD/tweets","defaultTab":"tweets","newsList":[{"id":"2658977424","title":"Lifeward Ltd Expected to Post a Loss of $1.34 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658977424","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658977424?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:40","pubTimestamp":1786538406,"startTime":"0","endTime":"0","summary":"Lifeward Ltd <LFWD.OQ> expected to post a loss of $1.34 a share - Earnings PreviewLifeward LtdLFWD.OQ,LFWD.Ois expected to  show a rise in quarterly revenue when it reports  results on August 14 for the period ending June 30 2026The Yokneam Northern -based  company is expected to report a 14.1% increase in revenue to $6.531 million from $5.72 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.LSEG's mean analyst estimate for Lifeward Ltd is for a loss of $1.34 per share.The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Lifeward Ltd is $20.00, about 164.4% above its last closing price of $7.57This summary was machine generated August 12 at 12:40 GMT.  All figures in US dollars unless otherwise stated.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL8N44916E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","LFWD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108790239","title":"Goldman Sachs: AI's Next Main Line Shifts From Computing Power To Humanoid Robots","url":"https://stock-news.laohu8.com/highlight/detail?id=1108790239","media":"Analyst Calls","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108790239?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:55","pubTimestamp":1786449320,"startTime":"0","endTime":"0","summary":"","market":"other","thumbnail":"https://static.tigerbbs.com/780d8f6b71029491c2d5db10e8614b00","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/780d8f6b71029491c2d5db10e8614b00"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Goldman Sachs: AI's Next Main Line Shifts From Computing Power To Humanoid Robots","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PDYN","SERV","GS","SYM","KITT","LFWD","IRBT","ARBE","MBOT","GFAI","STXS","RR"],"isVideo":true,"video":{"duration":117,"video_url":"https://news-video-sg.skytigris.cn/videos/cdn/324.mp4","video_thumbnail":"https://static.tigerbbs.com/780d8f6b71029491c2d5db10e8614b00","audio_url":"https://static.tigerbbs.com/cf44cfb2cae6eacdbbde3f20aa93795d.mp3","isAI":true},"gpt_icon":0},{"id":"2658600931","title":"Lifeward Ltd Expected to Post a Loss of $1.34 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658600931","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658600931?lang=en_us&edition=fundamental","pubTime":"2026-08-10 21:16","pubTimestamp":1786367765,"startTime":"0","endTime":"0","summary":"Lifeward Ltd <LFWD.OQ> expected to post a loss of $1.34 a share - Earnings PreviewLifeward LtdLFWD.OQ,LFWD.Ois expected to  show a rise in quarterly revenue when it reports  results on August 14 for the period ending June 30 2026The Yokneam Northern -based  company is expected to report a 14.1% increase in revenue to $6.531 million from $5.72 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.LSEG's mean analyst estimate for Lifeward Ltd is for a loss of $1.34 per share.The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Lifeward Ltd is $20.00, about 160.2% above its last closing price of $7.69This summary was machine generated August 10 at 13:16 GMT.  All figures in US dollars unless otherwise stated.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N44713J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFWD","BK4082","BK4604"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657439806","title":"Lifeward to Report Q2 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657439806","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657439806?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:02","pubTimestamp":1786104134,"startTime":"0","endTime":"0","summary":"Lifeward to report Q2 2026 financial resultsLifeward will release Q2 2026 financial results on Aug. 14, 2026, before 9:30 a.m. ET.A press release will be issued, with the quarterly report filed with t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDLw1BLb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4082","IE00BKPKM429.USD","SG9999014039.USD","IE00BGHQF748.EUR","LU2210149790.SGD","BCDF","IE00BN0W2T93.GBP","LU2210150020.SGD","SG9999014005.SGD","BK4585","SG9999014021.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","BK4604","LFWD","LU0314104364.USD","BK4588","IE00B3QW5Z07.USD","BK4112","LU2095319765.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657541108","title":"Lifeward Launches Pilot Program with Ottobock Care to Expand Access to ReWalk Personal Exoskeleton","url":"https://stock-news.laohu8.com/highlight/detail?id=2657541108","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657541108?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:00","pubTimestamp":1785931224,"startTime":"0","endTime":"0","summary":"Lifeward launches pilot program with Ottobock Care to expand access to ReWalk personal exoskeletonLifeward launched a six-month pilot program with Ottobock Care to expand U.S. patient access to the Re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDLp5xSR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","IE00BKPKM429.USD","BCDF","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4112","LFWD","LU2095319765.USD","LU0314104364.USD","SG9999014021.USD","BK4082","BK4585","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014005.SGD","BK4604","NDAQ","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","SG9999014039.USD","LU2210150020.SGD","SG9999014013.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653889817","title":"Nano Dimension Names Moshe Rozenbaum Interim CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2653889817","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653889817?lang=en_us&edition=fundamental","pubTime":"2026-07-22 04:10","pubTimestamp":1784664608,"startTime":"0","endTime":"0","summary":"Nano Dimension names Moshe Rozenbaum interim CEONano Dimension named Moshe Rozenbaum interim CEO, effective immediately, as the board reviews strategic priorities and options.Phillip Borenstein was ap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL2qXG3Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","BK4604","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4112","BK4082","BK4161","SG9999014039.USD","SG9999014021.USD","BK4585","BK4170","BK4588","IE00BN0W2W23.USD","LU0314104364.USD","LU2210149790.SGD","BK4546","NNDM","NDAQ","IE00BGHQF748.EUR","SG9999014005.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","LFWD","LU2210150020.SGD","LU2095319765.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649930411","title":"Lifeward Enters USD 5.58 Million Senior Secured Convertible Note Financing with Investors, Oramed Agent","url":"https://stock-news.laohu8.com/highlight/detail?id=2649930411","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649930411?lang=en_us&edition=fundamental","pubTime":"2026-07-08 04:31","pubTimestamp":1783456297,"startTime":"0","endTime":"0","summary":"Lifeward enters USD 5.58 million senior secured convertible note financing with investors, Oramed agentLifeward entered a securities purchase agreement for senior secured convertible notes with certai","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDLbDhQ9p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFWD","BK4082","BK4604"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649937709","title":"Press Release: Lifeward Secures Growth Capital to Accelerate Commercial Expansion with up to $11.2 Million in Strategic Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2649937709","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649937709?lang=en_us&edition=fundamental","pubTime":"2026-07-08 04:15","pubTimestamp":1783455300,"startTime":"0","endTime":"0","summary":"-- Lifeward's ordinary shares trading at or above $13.80 per share for ten","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","AAQC","BK4588","BK4082","BK4585","TM","BK4022","BK4555","BK4099","R","LFWD","BK4232","BK4604"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637873392","title":"Lifeward Q1 FY26 net loss widens to $10.79 million; revenue drops 22% to $3.92 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2637873392","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637873392?lang=en_us&edition=fundamental","pubTime":"2026-05-21 04:25","pubTimestamp":1779308747,"startTime":"0","endTime":"0","summary":"Lifeward posted a net loss of $10.79 million, widening from $4.83 million a year earlier.Revenue fell 22% to $3.92 million, driven by a roughly $1.3 million decline in AlterG on lower unit shipments tied to working-capital-related sourcing and supply-chain timing issues.Operating loss widened to $10.34 million as research and development expenses more than doubled to $5.85 million, reflecting a roughly $4.9 million one-time acquired IPR&D charge tied to the Oratech acquisition.Cash and cash equivalents totaled $11.4 million at March 31, 2026, with net cash used in operating activities improving 33% to $3.68 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content used to generate this news br","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL2QkD89:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFWD","BK4604","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636284471","title":"Lifeward files initial beneficial ownership statement for Chief Medical Officer Rose Keith Dale","url":"https://stock-news.laohu8.com/highlight/detail?id=2636284471","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636284471?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:14","pubTimestamp":1779279267,"startTime":"0","endTime":"0","summary":"Lifeward Chief Medical Officer Rose Keith Dale reported direct ownership of 2,083 ordinary shares in an initial Form 3 filing dated May 1, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL8yVb8z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFWD","BK4604","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636557568","title":"Lifeward names Keith D. Rose chief medical officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2636557568","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636557568?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:06","pubTimestamp":1779192419,"startTime":"0","endTime":"0","summary":"Rose previously served as vice president, medical affairs and medical director, neurosciences at the company.His prior senior roles included medical affairs and clinical leadership positions at Biocodex, Novocure, Ipsen Bioscience, Jazz Pharmaceuticals, and Indivior.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL318mJB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BN0W2T93.GBP","LU0823416689.USD","LU0889565916.HKD","IE00BN0W2V16.EUR","JAZZ","SG9999014005.SGD","LU0154245673.USD","NVCR","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","IE00B3QW5Z07.USD","BK4112","IE00BN0W2W23.USD","LFWD","LU2210149790.SGD","BK4604","LU0320765992.SGD","INDV","LU0109394709.USD","BK4585","SG9999014039.USD","BK4534","BK4533","BK4007","BK4548","BK4082","LU2095319765.USD","SG9999014013.SGD","SG9999014021.USD","LU0154245756.USD","LU2210150020.SGD","BK4532","BK4588","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636855168","title":"Press Release: Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2636855168","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636855168?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:00","pubTimestamp":1779192000,"startTime":"0","endTime":"0","summary":"Veteran physician, medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience, mobility technologies, and metabolic disease. Promotion reflects Lifeward's continued investment in clinical innovation, evidence generation, and patient outcomes across its expanding med-tech rehabilitation and biomed technology portfolio. \"Keith has already made a significant impact at Lifeward through his clinical leadership, scientific expertise, strategic insight, and deep commitment to patients,\" said Mark Grant, CEO of Lifeward. \"As we continue to broaden our rehabilitation technology portfolio and advance our newly acquired biomedical assets, Keith's extensive background in physical medicine, neuroscience, metabolic disease, and medical affairs makes him exceptionally well-positioned to help drive our next phase of growth.\". Dr. Rose brings more than three decades of experience in rehabilitation medicine, neuroscience, medical","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4588","LFWD","BK4022","TM","BK4555","R","03160","BK4099","BK4232","BK4604","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635035944","title":"Lifeward Ltd reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635035944","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635035944?lang=en_us&edition=fundamental","pubTime":"2026-05-15 23:09","pubTimestamp":1778857799,"startTime":"0","endTime":"0","summary":"Lifeward Ltd reports results for the quarter ended March 31 - Earnings SummaryLifeward Ltd LFWD.OQ reported a quarterly adjusted loss of $6.70 per share for the quarter ended March 31, lower than the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S1OR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFWD","BK4604","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635873760","title":"Lifeward delays Q1 10-Q filing, cites accounting work on strategic transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2635873760","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635873760?lang=en_us&edition=fundamental","pubTime":"2026-05-15 21:01","pubTimestamp":1778850112,"startTime":"0","endTime":"0","summary":"Lifeward filed a Form 12b-25 to delay its quarterly report on Form 10-Q for period ended March 31, 2026.Filing delayed to allow more time to finalize accounting tied to strategic transaction completed March 25, 2026, including valuation work and related accounting treatment.Form 10-Q expected within five calendar days of prescribed due date.Quarter expected to show revenue down about $1.1 million, or 22%, versus year-earlier period, driven mainly by about $1.3 million drop in AlterG revenue.Net loss expected to widen by about $6 million, or 123%, reflecting about $4.9 million one-time R&D expense tied to acquired in-process R&D assets, plus about $600,000 of financing expenses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Lt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL3kt5tq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFWD","BK4604","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635084116","title":"Lifeward Q1 Adj. EPS $(3.13) Misses $(1.25) Estimate, Sales $3.923M Miss $5.775M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635084116","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635084116?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:23","pubTimestamp":1778847835,"startTime":"0","endTime":"0","summary":"Lifeward Q1 Adj. EPS $(3.13) Misses $(1.25) Estimate, Sales $3.923M Miss $5.775M Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/LFWD","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFWD","BK4082","BK4604"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635081706","title":"Lifeward Q1 FY26 net loss more than doubles to $10.8 million; revenue falls 22% to $3.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635081706","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635081706?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:05","pubTimestamp":1778846715,"startTime":"0","endTime":"0","summary":"Lifeward posted Q1 net loss of $10.8 million, or $6.70 per share, widening from year-ago levels, as revenue fell 22% to $3.9 million.Operating loss widened to $10.3 million, driven by a one-time, non-cash R&D charge of about $4.9 million tied to acquired in-process R&D from the Oratech transaction.Gross margin slipped 8 percentage points to 34.2% on lower production volumes, higher tariffs, and foreign-exchange swings.Cash used in operating activities dropped 33% year over year to $3.7 million, while unrestricted cash and equivalents rose to $11.4 million following convertible notes proceeds and $6.5 million of cash acquired in the Oratech deal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL2K4mCt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFWD","LU1791710400.SGD","IE00BWXC8680.SGD","SG9999018857.SGD","LU0912757837.SGD","SG9999014880.SGD","LU2089284900.SGD","LU0122379950.USD","LU1814569148.SGD","LU0353189763.USD","LU1989771016.USD","LU0058720904.USD","LU2125154778.USD","LU1983260115.SGD","LU0689472784.USD","LU1037948897.HKD","LU1934455277.USD","LU0266013472.USD","IE00BFSS8Q28.SGD","LU0011850046.USD","SGXZ57979304.SGD","SGXZ99366536.SGD","IE00B775H168.HKD","LU1914381329.SGD","LU1066051498.USD","LU0348723411.USD","LU2324357040.USD","LU0187121727.USD","LU0052756011.USD","LU0823416689.USD","IE00B1BXHZ80.USD","IE00B19Z8X17.USD","LU0006061336.USD","LU2125909247.SGD","BK4588","LU2023251221.USD","IE00BFSS7M15.SGD","LU2089984988.USD","LU2357305700.SGD","SG9999013999.USD","LU0553294199.USD","LU1093756325.SGD","LU1267930573.SGD","LU2089283258.USD","LU0109391861.USD","LU0820562030.AUD","LU0211326755.USD","SG9999014906.USD","LU0203345920.USD","LU0353189680.USD","IE0002270589.USD","LU0029864427.USD","LU0077335932.USD","LU1732799900.SGD","LU2125909593.SGD","IE00BJJMRX11.SGD","LU2125154935.USD","IE0004445015.USD","LU0354030438.USD","LU1791710582.SGD","BK4082","LU0432979614.USD","IE00B19Z3B42.SGD","LU1670628061.USD","LU0820561909.HKD","IE0002141913.USD","LU2242649171.HKD","LU1066051225.USD","LU1720051108.HKD","LU0949170772.SGD","LU0149725797.USD","LU1854104046.USD","LU1261432733.SGD","LU0310800379.SGD","LU2361044949.HKD","SG9999002224.SGD","LU2461242641.AUD","LU0354030511.USD","IE00B19Z9P08.USD","LU2133065610.SGD","LU2279689827.SGD","IE00B4JS1V06.HKD","SG9999001176.SGD","IE00B2B36J28.USD","LU2491050154.USD","LU0238689110.USD","LU0661504455.SGD","LU0965509283.SGD","LU0345770308.USD","IE00BJT1NW94.SGD","LU1720051017.SGD","IE00B1XK9C88.USD","LU0162691827.USD","LU0943347566.SGD","LU2361044865.SGD","LU1548497426.USD","LU1074936037.SGD","LU1496350502.SGD","LU0251132253.USD","LU0965509101.SGD","LU2028103732.USD","LU1084165304.USD","LU1718418525.SGD","IE0005OL40V9.USD","BK4154","IE00BSNM7G36.USD","LU0417517546.SGD","LU0861579265.USD","LU1854103824.USD","LU1035773651.USD","LU0070302665.USD","SG9999014021.USD","LU0170899867.USD","IE00B19Z8W00.USD","LU0203347892.USD","SG9999014005.SGD","LU1093756168.USD","BK4534","LU0708995401.HKD","LU2491050071.SGD","BK4504","LU1267930227.SGD","LU1066051811.HKD","LU0094547139.USD","LU1732800096.USD","SG9999014898.SGD","LU2236285917.USD","IE00B894F039.SGD","LU2087625088.SGD","LU0079474960.USD","LU1323610961.USD","SG9999017495.SGD","LU0310800965.SGD","LU0795875169.SGD","LU0316494557.USD","LU1119994496.HKD","LU0211327993.USD","BK4566","LU0320765059.SGD","LU2552382058.USD","IE00BN29S564.USD","LU0787776722.HKD","LU2491049909.HKD","LU1023059063.AUD","LU0114720955.EUR","IE00BFXG1179.USD","LU0390134368.USD","IE00BJJMRZ35.SGD","IE00B19Z9505.USD","LU2361045086.USD","LU1670627923.USD","IE00B19Z9Z06.USD","LU1934455863.HKD","LU0053666078.USD","BK4532","LU1059921491.USD","LU0882574055.USD","LU0158827781.USD","LU0107464264.USD","LU0683600562.USD","LU0128525689.USD","LU1069347547.HKD","LU1551013425.SGD","LU2211815571.USD","LU1003077747.HKD","LU0061475181.USD","LU2362541273.HKD","IE00BKVL7J92.USD","LU1674673428.USD","LU2347655156.SGD","IE00B19Z3581.USD","LU1674673691.USD","LU1778281490.HKD","BK4585","IE00B7SZLL34.SGD","LU0557290698.USD","LU1061106388.HKD","LU1506573853.SGD","LU1934455194.USD","SG9999018865.SGD","LU0158827948.USD","LU0342679015.USD","LU0528227936.USD","LU2111349929.HKD","LU0310799852.SGD","IE00B7KXQ091.USD","LU0545039389.USD","LU0211326839.USD","LU0198837287.USD","LU0289739699.SGD","LU0048584097.USD","LU0965509010.AUD","UNHG","IE00BKPKM429.USD","LU1983299246.USD","BK4196","LU0128525929.USD","LU2362540622.SGD","SG9999001176.USD","LU0072461881.USD","UNHW","LU2244417387.USD","LU2360032135.SGD","LU0795875086.SGD","LU0211328371.USD","IE00BJJMRY28.SGD","LU0211331839.USD","BK4581","LU1923622614.USD","LU1291159041.SGD","LU0672654240.SGD","BK4533","LU1066053197.SGD","LU2552382132.HKD","LU1057294990.SGD","IE00BZ9MQY76.HKD","LU2112291526.USD","LU0738911758.USD","LU2468319806.SGD","IE0009355771.USD","LU1988902786.USD","LU0256863811.USD","SG9999002232.USD","LU1267930490.SGD","BK4550","LU1551013342.USD","LU0456855351.SGD","IE00BZ1G4Q59.USD","IE000M9KFDE8.USD","SG9999014013.SGD","LU0345770993.USD","LU0496365809.HKD","IE00BFTCPJ56.SGD","SGXZ51526630.SGD","LU0965508806.USD","SGXZ81514606.USD","LU1037948541.HKD","LU2433249047.HKD","LU1571399168.USD","LU0320765489.SGD","LU2271345857.HKD","LU1153585028.USD","LU1699723380.USD","LU0708994859.HKD","LU2362541513.USD","LU1267930730.SGD","LU1064131342.USD","LU2552382215.SGD","IE00B4R5TH58.HKD","LU2264538146.SGD","LU0208291251.USD","SG9999014914.USD","LU0976567544.SGD","LU0234572021.USD","LU0097036916.USD","LU0820561818.USD","IE0004445239.USD","BK4604","SGXZ31699556.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635081433","title":"Press Release: Lifeward Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635081433","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635081433?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:01","pubTimestamp":1778846460,"startTime":"0","endTime":"0","summary":"Oramed strategic transaction successfully closed and $10 million financing received. Oratech acquisition brings $6.5 million in cash and promising Protein Oral Delivery biomed technology, with lead asset ORMD-0801 oral insulin set to commence Phase 2 study. Acquired upper body exoskeleton technology addressing unmet need in 4.6 million stroke survivors. Quarterly operating cash burn reduced by 33% year-over-year, reflecting improved operational efficiencies and working capital management. -- Strategic transaction closed with equity-based acquisition of Oratech:. ORMD-0801 oral insulin Phase 2 trial set to commence: Trial activities to be managed by Oramed utilizing Oratech transaction funds. -- Upper body powered exoskeleton technology addresses unmet need in 4.6. million stroke survivors: The Company entered into an agreement during. the first quarter of 2026 to acquire technology with integrated AI. capabilities designed to assist individuals with upper-limb mobility. -- ReWalk perso","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","03160","BK4555","BK4588","BK4232","BK4604","TM","BK4022","BK4082","BK4585","BK4099","LFWD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635729065","title":"Lifeward files initial beneficial ownership statement for Oramed Pharmaceuticals stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2635729065","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635729065?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:20","pubTimestamp":1778793609,"startTime":"0","endTime":"0","summary":"Lifeward Ltd. Form 3 filing shows Oramed Pharmaceuticals as a 10% owner, reporting event date March 25, 2026.Additional exposure through derivative positions tied to ordinary shares, including 1,006,113 pre-funded warrants at USD 0 exercise price.Warrants for 1,296,296 ordinary shares at USD 5.4, warrants for 1,666,666 ordinary shares at USD 5.4, senior secured convertible notes convertible into 1,666,666 ordinary shares at USD 5.4.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 14, 2026, and is solely responsible for the i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDLHZBMN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP","BK4082","BK4007","LFWD","BK4604"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635733566","title":"Lifeward Ltd  expected to post a loss of $1.25 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2635733566","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635733566?lang=en_us&edition=fundamental","pubTime":"2026-05-13 22:19","pubTimestamp":1778681946,"startTime":"0","endTime":"0","summary":"Lifeward Ltd  expected to post a loss of $1.25 a share - Earnings Preview Lifeward Ltd LFWD.OQ, LFWD.O is expected to  show a rise in quarterly revenue when it reports  results on May 15 for the perio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q202:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4604","LFWD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634028758","title":"Lifeward Ltd  expected to post a loss of $1.25 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634028758","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634028758?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:51","pubTimestamp":1778507470,"startTime":"0","endTime":"0","summary":"Lifeward Ltd  expected to post a loss of $1.25 a share - Earnings Preview Lifeward Ltd LFWD.OQ, LFWD.O is expected to  show a rise in quarterly revenue when it reports  results on May 13 (estimated) f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O1IX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFWD","BK4082","BK4604"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.golifeward.com","stockEarnings":[{"period":"1week","weight":0.0492},{"period":"1month","weight":-0.0978},{"period":"3month","weight":0.141},{"period":"6month","weight":0.2361},{"period":"1year","weight":-0.0813},{"period":"ytd","weight":0.0933}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":0.0207},{"period":"3month","weight":0.0381},{"period":"6month","weight":0.1311},{"period":"1year","weight":0.2117},{"period":"ytd","weight":0.13}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.091793},{"month":2,"riseRate":0.5,"avgChangeRate":-0.042859},{"month":3,"riseRate":0.083333,"avgChangeRate":-0.12159},{"month":4,"riseRate":0.166667,"avgChangeRate":0.018432},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.024843},{"month":6,"riseRate":0.25,"avgChangeRate":-0.000932},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.03289},{"month":8,"riseRate":0.25,"avgChangeRate":-0.06505},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.017608},{"month":10,"riseRate":0.25,"avgChangeRate":-0.11045},{"month":11,"riseRate":0.166667,"avgChangeRate":-0.100673},{"month":12,"riseRate":0.25,"avgChangeRate":-0.017045}],"exchange":"NASDAQ","name":"Lifeward Ltd","nameEN":"Lifeward Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lifeward Ltd(LFWD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lifeward Ltd(LFWD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lifeward Ltd,LFWD,Lifeward Ltd股票,Lifeward Ltd股票老虎,Lifeward Ltd股票老虎国际,Lifeward Ltd行情,Lifeward Ltd股票行情,Lifeward Ltd股价,Lifeward Ltd股市,Lifeward Ltd股票价格,Lifeward Ltd股票交易,Lifeward Ltd股票购买,Lifeward Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lifeward Ltd(LFWD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lifeward Ltd(LFWD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction